{"id":61755,"date":"2025-08-21T13:07:08","date_gmt":"2025-08-21T11:07:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/"},"modified":"2025-08-21T13:07:08","modified_gmt":"2025-08-21T11:07:08","slug":"strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/","title":{"rendered":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer"},"content":{"rendered":"
\n

\nLeader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator<\/i><\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

BOSTON–(BUSINESS WIRE)–Strand Therapeutics, the leader in programmable mRNA medicines, today announced the appointment of Jason J. Luke, MD, FACP, as Chief Medical Officer. Dr. Luke, an internationally recognized physician-scientist in cancer immunotherapy, brings decades of clinical research, translational science, and leadership experience to advance Strand\u2019s mission of developing next-generation mRNA therapeutics for patients with high unmet medical needs.<\/p>\n

\nDr. Luke joins Strand from the University of Pittsburgh and UPMC Hillman Cancer Center, where he served as Associate Professor of Medicine, Associate Director for Clinical Research and Director of the Immunotherapy and Drug Development Center. A pioneer in early-phase clinical trials, Dr. Luke has led transformative research in immuno-oncology, including checkpoint inhibitors, novel cytokines, bispecific antibodies, and cancer vaccines. He has served as principal investigator for more than 100 clinical studies, including as global principal investigator for the FDA\/EMA registration trial KEYNOTE-716 that established adjuvant therapy for stage II melanoma. Dr. Luke\u2019s National Institutes of Health funded laboratory efforts focused on bio- and medical informatics, novel therapeutic target discovery and translational analysis of human biospecimens from clinical trials. He is widely published in top-tier journals such as Nature, The Lancet, and Journal of Clinical Oncology.<\/p>\n

\nAs CMO, Dr. Luke will oversee Strand\u2019s clinical development strategy, pipeline advancement, and medical affairs, with an immediate focus on the company\u2019s ongoing first-in-human clinical trial of its lead programmable mRNA therapy STX-001. Dr. Luke was previously an advisor to Strand for the clinical trial design and a site PI on the study.<\/p>\n

\n\u201cJason is one of the most respected clinician-researchers in cancer immunotherapy, with a rare combination of deep scientific insight and a patient-first mindset,\u201d said Jake Becraft, PhD, Co-founder and Chief Executive Officer of Strand Therapeutics. \u201cHis leadership will be invaluable as we expand our clinical programs and unlock the full potential of programmable mRNA medicines.\u201d<\/p>\n

\n\u201cI am thrilled to join Strand at such a pivotal moment in the field,\u201d said Dr. Luke. \u201cProgrammable mRNA is an unprecedented platform to engineer sophisticated biological functions in vivo. Strand\u2019s approach has the potential to transform cancer treatment and impact other high unmet need areas in biomedicine. I look forward to working with the team to bring these innovations to patients as quickly and safely as possible.\u201d<\/p>\n

\nDr. Luke earned his MD from Rosalind Franklin University of Medicine and Science\/Chicago Medical School and completed his internal medicine residency at Boston University Medical Center. He then trained in medical oncology at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center. He was previously faculty of Harvard Medical School\/Dana-Farber Cancer Institute and the University of Chicago. His work has earned him multiple awards, including recognition from the American Society of Clinical Oncology and the National Cancer Institute.<\/p>\n

\nAbout Strand Therapeutics<\/b><\/p>\n

\nStrand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand\u2019s platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes.<\/p>\n

\nBorn out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying\/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond.<\/p>\n

\nStrand\u2019s lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage \u201csalvage\u201d cancer patients, with multiple patients showing RECIST responses. Strand\u2019s modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn\u2019t just another mRNA company: it\u2019s the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn<\/a> and on X at @strandtx.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Karen Sharma
\n
Ksharma@cglife.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator BOSTON–(BUSINESS WIRE)–Strand Therapeutics, the leader in programmable mRNA medicines, today announced the appointment of Jason J. Luke, MD, FACP, as Chief Medical Officer. Dr. Luke, an internationally recognized physician-scientist in cancer immunotherapy, brings decades of clinical research, translational science, and leadership experience … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61755","6":"format-standard","7":"category-industry"},"yoast_head":"\nStrand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator BOSTON–(BUSINESS WIRE)–Strand Therapeutics, the leader in programmable mRNA medicines, today announced the appointment of Jason J. Luke, MD, FACP, as Chief Medical Officer. Dr. Luke, an internationally recognized physician-scientist in cancer immunotherapy, brings decades of clinical research, translational science, and leadership experience ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T11:07:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer\",\"datePublished\":\"2025-08-21T11:07:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/\"},\"wordCount\":668,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250821223254\\\/en\\\/2557735\\\/22\\\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/\",\"name\":\"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250821223254\\\/en\\\/2557735\\\/22\\\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg\",\"datePublished\":\"2025-08-21T11:07:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250821223254\\\/en\\\/2557735\\\/22\\\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250821223254\\\/en\\\/2557735\\\/22\\\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend","og_description":"Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator BOSTON–(BUSINESS WIRE)–Strand Therapeutics, the leader in programmable mRNA medicines, today announced the appointment of Jason J. Luke, MD, FACP, as Chief Medical Officer. Dr. Luke, an internationally recognized physician-scientist in cancer immunotherapy, brings decades of clinical research, translational science, and leadership experience ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-21T11:07:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer","datePublished":"2025-08-21T11:07:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/"},"wordCount":668,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/","name":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg","datePublished":"2025-08-21T11:07:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250821223254\/en\/2557735\/22\/LUKE_JASON_MD_ON_20230110_headshot_hi_res.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/strand-therapeutics-appoints-dr-jason-j-luke-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61755"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61755\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}